Genmab | GEN - Gewinn Vor Steuern

Aktienkurs
1,712.50
Täglich Wechseln
-9.50 -0.55%
Monatlich
-1.78%
Jährlich
25.92%
Q2 Prognose
1,604.35




Gewinn Vor Steuern Veränderung Datum
Agios Pharmaceuticals USD -99.11M 9.94M 2026-03
Almirall EUR 30.32M 22M 2025-12
Amarin USD -852K 7.26M 2025-12
Amgen USD 1.51B 2.41B 2025-12
argenx SE USD 403.29M 17.24M 2025-12
AstraZeneca USD 3.91B 1.28B 2026-03
Bayer EUR -3.37B 2.21B 2025-12
BioMarin Pharmaceutical USD 141.2M 168.36M 2026-03
Demant DKK 1.64B 173M 2025-12
Exelixis USD 267.69M 15M 2026-03
Fresenius Medical Care EUR 340M 168.46M 2026-03
Genmab DKK 55M 427M 2025-12
GlaxoSmithKline GBP 2.14B 919M 2026-03
GN Store Nord DKK 450M 332M 2025-12
GRIFOLS EUR 190.51M 20.03M 2025-06
Hikma Pharmaceutical USD 147.5M 3.5M 2025-06
Insmed USD -162.1M 164.84M 2026-03
Lakefront Biotherapeutics EUR 13.96M 769.2M 2026-03
Lonza CHF 624M 197M 2024-12
Merck EUR 401M 886.1M 2025-12
Novartis USD 3.84B 802M 2026-03
Regeneron Pharmaceuticals USD 1.04B 719.6M 2025-12
Roche Holding CHF 4.79B 3.01B 2025-06
Sanofi EUR -1.16B 5.5B 2025-12
UCB EUR 789M 427M 2025-06